Clinical Trial Update: Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety, pharmacokinetics, and pharmacodynamics of BAY73-4506 in combination with mFOLFOX6 or FOLFIRI for colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• BAY73-4506 (BAY-73-4506)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Bayer | Conditions: Colorectal Neoplasms | Phase 1 | Status: COMPLETED